抗癌药研发的新策略：纳米靶向的高分子偶联抗癌症干细胞药物

摘要

In the past 20 years,a total of 5 polymer - drug conjugates(including 3 antibody - drug conjugates)have been approved by FDA for market sale. Besides these,many polymer - drug conjugates have been moved to clinical trials. As a very small subpopulation in tumor(only 0. 1% ~ 5% ),the cancer stem cell(cSc)is the root to cause drug resistance, relapse and metastasis of cancer. In the past few years,great progress has been made on the investigation of the anti - cSc drugs. About 30 anti - cSc investigational new drugs have been advanced to clinical trials. Synthesis of polymer -(anti -cSc drug)conjugates can help to solve the problems of anti - cSc drugs such as poor aqueous solubility,poor metabolic stability,side - effect,drug resistance,targetability,etc. Overall,combining polymer therapeutics nanomedicine with the anti - cSc drugs and synthesizing polymer -(anti - cSc drug)conjugates has brought new hope for curing the cancer and possesses bright prospect.%过去二十多年来，已有5个高分子偶联抗癌药（包括3个抗体偶联药物）被 FDA 批准进入市场，此外还有很多高分子偶联抗癌药被推向临床试验。作为肿瘤中存在的很小的细胞亚群（只占0.1%~5%），癌症干细胞是导致肿瘤耐药、复发和转移的根源。过去几年来，抗癌症干细胞药物的研究获得了飞速的进展，已有近30个抗癌症干细胞药物被推向临床试验。合成高分子偶联抗癌症干细胞药物有助于解决抗癌症干细胞药物水溶性差、代谢稳定性差、毒副作用、抗药性、靶向性等问题。将高分子治疗纳米医学与抗癌症干细胞药物结合，合成高分子偶联抗癌症干细胞药物，在与传统抗癌药联用的情况下，既能清除癌症干细胞，又能杀灭癌细胞，为治愈癌症带来了新的希望，具有极其广阔的前景。